A Randomized, Double-Blind, Phase 3 Comparison of Platinum-based Therapy with TSR-042 and Niraparib versus Standard of Care Platinum-based Therapy as First Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer